Autoantibodies to nuclear valosin-containing protein-like protein: systemic sclerosis-specific antibodies revealed by in vitro human proteome.

Autor:	Matsuda KM; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Kotani H; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Yamaguchi K; ProteoBridge Corporation, Tokyo, Japan., Ono C; ProteoBridge Corporation, Tokyo, Japan., Okumura T; ProteoBridge Corporation, Tokyo, Japan., Ogawa K; ProteoBridge Corporation, Tokyo, Japan., Miya A; ProteoBridge Corporation, Tokyo, Japan., Sato A; ProteoBridge Corporation, Tokyo, Japan., Uchino R; NOV Academic Research, TOKIWA Pharmaceutical Co., Ltd, Tokyo, Japan., Yumi M; NOV Academic Research, TOKIWA Pharmaceutical Co., Ltd, Tokyo, Japan., Matsunaka H; NOV Academic Research, TOKIWA Pharmaceutical Co., Ltd, Tokyo, Japan., Kono M; Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Norimatsu Y; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Hisamoto T; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Kawanabe R; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Kuzumi A; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Fukasawa T; Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Yoshizaki-Ogawa A; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Okamura T; Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Shoda H; Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Fujio K; Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Matsushita T; Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Ishikawa, Japan., Goshima N; ProteoBridge Corporation, Tokyo, Japan., Sato S; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan., Yoshizaki A; Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.; Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Oct 01; Vol. 63 (10), pp. 2865-2873.
DOI:	10.1093/rheumatology/keae063
Abstrakt:	Objectives: To identify and characterize undescribed systemic sclerosis (SSc)-specific autoantibodies targeting nucleolar antigens and to assess their clinical significance. Methods: We conducted proteome-wide autoantibody screening (PWAS) against serum samples from SSc patients with nucleolar patterned anti-nuclear antibodies (NUC-ANAs) of specific antibodies (Abs) unknown, utilizing wet protein arrays fabricated from in vitro human proteome. Controls included SSc patients with already-known SSc-specific autoantibodies, patients with other connective tissue diseases and healthy subjects. The selection of nucleolar antigens was performed by database search in the Human Protein Atlas. The presence of autoantibodies was certified by immunoblots and immunoprecipitations. Indirect immunofluorescence assays on HEp-2 cells were also conducted. Clinical assessment was conducted by retrospective review of electronic medical records. Results: PWAS identified three candidate autoantibodies, including anti-nuclear valosin-containing protein-like (NVL) Ab. Additional measurements in disease controls revealed that only anti-NVL Abs are exclusively detected in SSc. Detection of anti-NVL Abs was reproduced by conventional assays such as immunoblotting and immunoprecipitation. Indirect immunofluorescence assays demonstrated homogeneous nucleolar patterns. Anti-NVL Ab-positive cases were characterized by significantly low prevalence of diffuse skin sclerosis and interstitial lung disease, compared with SSc cases with NUC-ANAs other than anti-NVL Abs, such as anti-U3-RNP and anti-Th/To Abs. Conclusion: Anti-NVL Ab is an SSc-specific autoantibody associated with a unique combination of clinical features, including limited skin sclerosis and lack of lung involvement. (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu